Inicio/Acciones/ALXO

ALXO

USD

ALX Oncology Holdings Inc. Common Stock

$1.460-0.060 (-3.947%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.520

Máximo

$1.600

Mínimo

$1.460

Volumen

0.54M

Fundamentos de la Empresa

Capitalización de Mercado

78.2M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.93M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $0.404Actual $1.460Máximo $2.27

Noticias Relacionadas

30 oct 2025 · 12:30

GlobeNewswire

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

23 oct 2025 · 16:30

GlobeNewswire

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports